Identification of ultra-rare genetic variants in Pediatric Acute Onset Neuropsychiatric Syndrome (PANS) by exome and whole genome sequencing

Rosario Trifiletti, Herbert M. Lachman, Olivia Manusama, Deyou Zheng, Alberto Spalice, Pietro Chiurazzi, Allan Schornagel, Andreea M. Serban, Rogier van Wijck, Sigrid Swagemakers, Peter J. van der Spek
doi: https://doi.org/10.1101/2021.05.25.21257256

Abstract

Pediatric acute onset neuropsychiatric syndrome (PANS) is viewed as an autoimmune/autoinflammatory condition characterized by the abrupt onset of severe neurological and psychiatric symptoms, in particular obsessive-compulsive disorder (OCD), tics, anxiety, mood swings, irritability, and restricted eating, often triggered by infections. However, direct evidence of autoimmunity, infections, or a proinflammatory state is often lacking, and there is no unifying pathogenic pathway. This could be due to underlying genetic heterogeneity, which could lead to the development of PANS through different cellular and molecular pathways. Unfortunately, little is known about the genetic basis of PANS. Consequently, we carried out whole exome sequencing (WES) on a U.S. cohort of 386 cases who met diagnostic criteria for PANS, including 133 family triads, and whole genome sequencing (WGS) on ten cases from the European Union, who were selected for WGS because of severe PANS symptoms. We focused on identifying potentially deleterious genetic variants that were either de novo or ultra-rare with a minor allele frequency (MAF) < 0.001. Candidate mutations were found in 11 genes: PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1 in a total of 20 cases, which included two sets of siblings, and two or more unrelated subjects with ultra-rare variants in SGCE, NLRC4, RAG1, and SHANK3. The PANS candidate genes we identified separate into two broad functional categories. One group regulates peripheral innate and adaptive immune responses (e.g., PPM1D, CHK2, NLRC4, RAG1, PLCG2), some of which also influence microglia function. Another is expressed primarily at neuronal synapses or directly modulates synaptic function (SHANK3, SYNGAP1, GRIN2A, GABRG2, CACNA1B, SGCE). These neuronal PANS candidate genes are often mutated in autism spectrum disorder, developmental disorders, and myoclonus-dystonia. In fact, eight out of 20 cases in this study developed PANS superimposed on a preexisting neurodevelopmental disorder. There is, however, clinical overlap between these two groups and some crossover expression (e.g., some neuronal genes are expressed in immune cells and vice versa) that diminishes the neuronal/immune dichotomy. Genes in both categories are also highly expressed in the enteric nervous system, and in the choroid plexus and brain vasculature, suggesting they might contribute to a breach in the blood-CSF barrier and blood-brain barrier (BBB) that would permit the entry of autoantibodies, inflammatory cytokines, chemokines, prostaglandins, and autoantibodies into the brain. Thus, PANS is a genetically heterogeneous condition that can occur as a stand-alone neuropsychiatric condition or co-morbid with neurodevelopmental disorders, with candidate genes functioning at several levels of the neuroinflammatory axis.

Introduction

The clinical entity known as PANS emerged from problems related to the diagnosis of PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections). In its original description, PANDAS was characterized by acute onset obsessive-compulsive disorder (OCD) and tics following infection with group A beta-hemolytic streptococcus (GABHS)1, 2. The concept of PANS was introduced a decade later to expand the diagnosis to include a multitude of acute-onset neuropsychiatric problems and exclude the requirement of GABHS infection and tics (Table 1) 3. PANDAS is now considered as a subgroup of PANS, although some controversy remains. While some investigators have reported the presence of autoantibodies against neuronal antigens and elevated levels of inflammatory cytokines in PANS, these findings are inconsistent and the validity of the Cunningham panel of 5 biomarkers used in diagnosing PANS has been supported in some studies and questioned in others 4–6. Imaging studies in some PANS cases show local inflammation in the thalamus, basal ganglia, and amygdala, supporting a neuroinflammatory or autoimmune etiology. In addition, many patients respond to immunomodulators, such as non-steroidal anti-inflammatory drugs (NSAIDs), intravenous immunoglobulin (IVIG), corticosteroids, and more recently, the B-cell inhibitor Rituximab 4, 8. However, this finding is controversial as some investigators have expressed concerns about the dearth of large, well-controlled clinical trials 6, 7, 9. Because of these issues and the lack of consistent, objective biomarkers, many children remain undiagnosed and undertreated, adversely affecting both patients and their families, and perhaps contributing to disease chronicity. According to the Stanford PANS Clinic, the median Caregiver Burden Inventory (CBI) during a 1st PANS flare is 37, which is higher than the CBI for those caring for someone with Alzheimer disease and similar to that found in Rett syndrome 10. Although most children with PANS show significant improvement at follow-up, according to a recently published longitudinal study, full remission was rare, and more than one-third were classified as having a chronic course 11.

View this table:
Table 1.

Diagnostic criteria for PANS/PANDAS adapted from reference 3 and NIMH (see Web Resources)

One plausible explanation for the inconsistent findings related to the presence or absence of autoantibodies and inflammatory markers, and the relationship to infectious pathogens, is heterogeneity in the infectious diseases other than GABHS, such as Mycoplasma pneumoniae, Borrelia burgdorferi and influenza virus, that might act as autoimmune or proinflammatory triggers 12. Another possibility is that non-infectious environmental factors that activate innate immune pathways (i.e. sterile or non-infectious inflammation), such as oxidative stress, exposure to toxins, or emotional stress, could trigger an abnormal inflammatory response in genetically susceptible children. Finally, heterogeneity in genetic risk factors that cause dysregulation of peripheral immunity, or central neuronal/innate immune pathways could be at play, all leading to a common clinical phenotype. In this model, some genetic subgroups will express classic markers of inflammation or autoantibodies, but not others. However, gene discovery in PANS that can test this model is still in its infancy.

Whole exome sequencing (WES) and whole genome sequencing (WGS) are gene discovery tools used by researchers, and increasingly by clinicians, to identify ultra-rare, biologically powerful genetic factors underlying disease states. However, such studies have not yet been reported in PANS. We now describe the discovery of ultra-rare variants in 11 genes in 20 PANS cases using WES and WGS technologies.

Subjects and Methods

Subjects

The European subjects were identified through a call for patients with severe symptoms from a PANS/PANDAS advocacy group called EXPAND after a teenage girl with chronic PANS was found to have an ultra-rare variant in the PPM1D gene by WGS. EXPAND is a European advocacy organization for families of children and adolescents with immune-mediated neuropsychiatric disorders. Parents, caretakers, or patients signed informed consents approved by the Ethical Committee at Erasmus MC (MEC-2011-253 for control samples and MEC-2021-0359 for PANS patients; IRB/ Human Subject Assurance number/Federal Wide Assurance, FWA00001336). Histories from this cohort were obtained by the participating physicians and collated by one of the co-authors (O.M).

Cases from the U.S. were obtained from a large private practice run by one of the authors (R.T) devoted to PANS (PANDAS/PANS Institute, Ramsey, NJ). 383 PANS cases and 263 controls that included 133 triads had WES carried out by Centogene (see below) (Rostock, Germany). The subjects signed an informed consent by Centogene to which they agreed to provide anonymized genetic information for research purposes. The corresponding author has IRB approval from the Albert Einstein College of Medicine to obtain and analyze deidentified data from human subjects (approval ID, 2000-014). Each case in the U.S. cohort was personally treated by one physician (R.T) who obtained a detailed personal and family history.

To protect patient confidentiality, detailed histories are only available upon request to the corresponding author. The consenting parents and participants have agreed to have the results of this research work published.

WGS and WES data analysis

The EU cases were sequenced using DAB nanoball sequencing for WGS and Illumina for WES. We implemented ANNOVAR, an efficient software tool that utilizes up-to-date information to functionally annotate genetic variants and allele frequencies detected in each patient’s genome. In addition to gene-based annotation, ANNOVAR is used for region-based annotations to identify variants in specific genomic regions, such as ultra-conserved regions across species (Vista database), predicted transcription factor binding sites (Transfac), segmental duplication regions, genome wide association study (GWAS) hits, database of genomic variants, DNAse I hypersensitivity sites, ENCODE H3K4Me1/H3K4Me3/H3K27Ac/CTCF sites, ChIP-Seq peaks, RNA-Seq peaks, and other annotations in genomic intervals. DNA nanoball sequencing has been applied for WGS to study non-coding regions and in particular variants within the ultra-conserved regulatory regions. This provided highly reliable variant lists that were compared with our selected variants and filtered based on allele frequency in GNOMAD ClinVar (public NCBI repository derived data). Only variants that occurred in patients and are never detected in 597 healthy elderly (Welderly) sample genomes were considered 13. DNA Nanoball sequencing protocol is detailed in the classic paper by Drmanac et al 14. The ultra-rare variant assessment was confirmed using additional cohorts that have been sequenced by the Erasmus MC team headed by one of us (P.S.).

The U.S. samples were sequenced by Centogene using double stranded DNA capture baits against approximately 36.5 Mb of the human coding exome (targeting >98% of the coding elements). RefSeq from the human genome build GRCh37/hg19) are used to enrich target regions from fragmented genomic DNA with the Twist Human Core Exome Plus kit. The generated library was sequenced on an Illumina platform to obtain at least 20x coverage depth for >98% of the targeted bases. The investigation for relevant variants focused on coding exons and flanking +/-20 intronic nucleotides of genes with a clear gene-phenotype evidence (based on OMIM® information). The resulting variant call (VCF) file was then subjected to a custom pipeline developed at the PANDAS/PANS Institute. For this study, we searched for variants with all of the following properties: 1) minor allele frequency (MAF) of <0.001: 2) American College of Medical Genetics Class 5 or 4 (i.e., “pathogenic” or “likely pathogenic”): 3) among a PANDAS/PANS institute cohort of 383 cases and 263 controls variants that were never observed, with rare exceptions noted, in controls.

Network analysis

Functional analysis was performed within Ingenuity Pathway Analysis (IPA) (QIAGEN Inc.). All candidate genes were imported in IPA to assess the pathways involved. Two additional, unpublished, PANS candidate genes (MTHC2 and BID) were added to the analysis. Using the network tool within IPA, a connectivity network was constructed based on the IPA/QIAGEN Knowledge Base. Both direct and indirect relationships were used to construct the biological network.

RNA expression analysis

The gene expression profiles of the candidate genes were analyzed using several datasets. First, we hypothesized that microglia might play a critical role in the PANS phenotype especially after an inflammatory stimulus. Consequently, a subset of 159 autism and pediatric immune disorder genes was analyzed based on a public dataset investigating the effect of LPS on murine microglia and macrophages (GSE102482) 15. After Robust Multichip Average normalization (RMA), a statistical analysis of microarray (SAM) was performed between non-stimulated microglia and LPS-stimulated microglia within OmniViz version 6.1.13.0 (Instem Scientific). The top 15 up-regulated and down-regulated genes were selected for visualization and further analysis.

Next, we investigated the gene expression profiles of our 11 PANS-associated candidates in peripheral blood mononuclear cells (PBMCs) under baseline conditions and after infection as many patients develop PANS symptoms following infections. Given the rising reporting of neuropsychiatric symptoms after COVID-19 infection, we used a recently published single cell RNA-seq (sc-RNA-seq) COVID-19 dataset to investigate the gene expression profiles16. This database contains gene expression patterns in control samples (N=6) and hospitalized severe COVID-19 patients (N=7).

To investigate the expression of the candidate genes in normal human tissue we used the Genotype-Tissue Expression (GTEx) dataset 17. We used the GTEx Multi Gene Query available on the GTEx portal to construct the RNA profiles in normal human tissue lineages. Finally, as the GTEx portal uses bulk RNA-seq data, we wanted to further investigate the gene expression profiles in more detail. Because neurological and psychiatric symptoms are cardinal in PANS, we were particularly interested in scRNA-seq in brain tissue. scRNA-seq data is not yet available for human brains, however, recently two datasets were published containing scRNA-seq data for adolescent and fetal mouse brains18, 19. All candidate genes were investigated in both datasets on the Mouse Brain Atlas portal.

Results

We identified ultra-rare variants in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 20 patients who met diagnostic criteria for PANS as established by the PANS Consensus Conference 3. The ultra-rare variants and brief descriptions of the cases are shown on Figure 1 and Table 2, respectively. In the European cohort, two affected siblings (cases 1 and 2) were found with an ultra-rare missense mutation in PPM1D (c.131C>G; p.S44W). They inherited the variant from an asymptomatic parent who has a family history autoimmune disorders, a common scenario in PANS families 20, 21. S44W is a known single nucleotide variant (SNV), rs373862041, with a minor allele frequency (MAF) of 0.000255, based on the TOPMed database of more than 125,000 samples 22. The ultra-rare variant in CACNA1B, found in two affected siblings (cases 3 and 4), is a 48 bp insert at the exon 2 splice donor site (c.390+1) that is predicted to disrupt splicing. It is part of a set of multiallelic insertion variants, rs370237172, that has an overall MAF of 0.017. However, the 48 bp insert is ultra-rare and has not been observed in control data sets. We have been unable to genotype the parents. Interestingly, the same 48 bp insert was identified in a young woman who has been incapacitated with chronic fatigue syndrome (myalgic encephalomyelitis) and anorexia (unpublished observations). This insert shows a 100% hit with a human oral metagenome assembly (unpublished results from ME/CFS project headed by Dr. Rogier Louwen, Erasmus MC).

Figure 1.
Figure 1.

Position of PANS ultra-rare variants within each candidate gene

View this table:
Table 2.

Summary of cases. Patient demographics, genetic variants, and brief clinical description. Bold type highlights cases with comorbid neurodevelopmental disorders, red type highlights those with a history of recurrent infections. For complete patient histories, see Supplemental Note: Case Reports. Abbreviations: pathogenic (P); likely pathogenic (LP); variant of unknown significance (VUS). To protect patient confidentiality, ages are not included. Each case showed the first signs of PANS before the age of 10.

Known transmission from a parent in the European cohort was also found in cases 9 and 10 (NLRC4: c.772T>C; p.C258R; and SGCE: del150 Iso; c.450_452, respectively), which will be discussed below. For the other ultra-rare variants, parental genotypes are not available. Remarkably, in the U.S. cohort, different ultra-rare variants were found in two of the same genes identified in the European cohort (NLRC4 and SGC2), and another, CHK2, codes for a well-established PPM1D substrate 23. A total of four different candidate variants were found in NLRC4, the most for any PANS-associated gene. Ultra-rare variants were also found in SHANK3 and RAG1 gene in three patients each. Case 17 has an ultra-rare variant in SHANK3 (c.4622C>T, P1541L) and a nonsense mutation in NLRC4 (c.928C>T, p.310X).

The finding of ultra-rare mutations in the same genes in unrelated individuals points to a true association.

These 11 genes separate into two broad functional categories; those that affect peripheral innate and adaptive immune pathways, and those that are expressed primarily in cortical neurons, where they function as synaptic regulators. Some of the immune genes also have significant effects on microglia, and the synaptic genes have all been implicated in other neurological and neurodevelopmental disorders. In addition, several neuronal genes are expressed in the choroid plexus and brain vasculature, suggesting they might contribute to a breach in the blood-CSF barrier and blood-brain barrier (BBB) that accompanies inflammation and infection. However, as described below, this dichotomy between immune and neuronal candidate genes is an over-simplification.

PANS candidate genes that primarily function in the peripheral immune system

PPM1D, CHK2, PLCG2, RAG1, and NLRC4 have well-established effects on peripheral innate and adaptive immunity. PPM1D codes for a serine/threonine phosphatase that negatively regulates p53 and other members of the DNA repair pathway. Somatic PPM1D gain of function mutations act as tumor suppressor genes 24–26. The most common are frameshift and nonsense mutations in exons 5 and 6 that lead to the production of a truncated protein that has a stabilizing effect on the retained catalytic portion. Germline exons 5 and 6 truncating mutations are found in children with Jansen de Vries Syndrome (JdVS) 27–31. JdVS is characterized by intellectual and developmental disabilities (IDD), restricted eating, high pain threshold, ASD, and psychiatric symptoms (primarily severe anxiety). Thus, there is some overlap in the clinical features observed in PANS and JdVS (e.g., restricted eating, anxiety). However, IDD is nearly universal in JdVS, while the two cases with the S44W variant excelled at school until the development of PANS, which became chronic, leading to persistent neuropsychiatric problems and academic regression. Most children with JdVS have a history of recurrent infections 27. However, no consistent immunological findings have been reported. PPM1D regulates T- and B-lymphocyte differentiation, and cytokine production, with Ppm1d deficient mice exhibiting a proinflammatory state following an immune challenge, and an increase in macrophage phagocytosis and autophagy 32–36. PPM1D has also been found to inhibit intestinal inflammation in inflammatory bowel disease and negatively regulates cytokine production in human neutrophils during sepsis 37. The proinflammatory state in Ppm1d null mice mimics that seen in PANS patients, suggesting that S44W may induce an exaggerated inflammatory response following an immune challenge through a loss-of-function effect on PPM1D catalytic activity in immune cells. Alternatively, a proinflammatory state could occur through disruption of immune responses caused by other regulatory proteins affected by S44W (see discussion).

Similar to PPM1D, CHK2 also codes for a regulator of the DNA repair response by phosphorylating p53 23, 38. Germline loss of function mutations in the kinase domain are found in several inherited cancer syndromes 39, 40. The protein encoded by CHK2 is expressed in T-cells and regulates IL-2 expression 41. The rare variant we identified, T410fsX14, is a truncating mutation in the distal end of the kinase domain and is probably a loss-of-function mutation. Chk2 inactivation in mouse B cells leads to decreased Ig hypermutation and Ig class switching 42, conditions that can, along with a DNA repair defect, lead to immune dysregulation 43–45. Defective DNA repair could also underlie the effects of the S44W PPM1D variant on immune function.

The finding of an ultra-rare variant in PPM1D and in one of its principal targets, CHK2, strongly supports the idea that these are indeed PANS-causing mutations.

PLCG2 is primarily expressed in B-cells, and gain-of-function mutations have been found in patients with severe sterile inflammation, recurrent bacterial infections, autoimmune disorders, and humoral immunodeficiency 46–49. The PLCG2 Y206F variant maps to the EF hand domain that binds calcium. Gain of function mutations in PLCG2 cause autoinflammatory disease through an increase in calcium influx upon B-cell activation 50. However, the effect of Y206F on calcium homeostasis awaits experimental validation.

NLRC4 codes for a component of the inflammasome, a cytosolic multiprotein complex that assembles in response to exogenous or endogenous stressors, thereby playing a major role in autoinflammatory diseases and macrophage activation syndrome 51–56. NLRC4 also regulates panoptosis, a recently identified inflammatory programmed cell death pathway, 57 and Th17 cells in mice exposed to osmotic stress 58.

A total of four patients with ultra-rare variants in NLRC4 were found in our two cohorts (including patient 17 who also has a SHANK3 variant). Two variants, c.772T>C (p.C258R) and c.928C>T (p.R310X) map to the NACHT domain, which has intrinsic ATPase activity and facilitates self-oligomerization 59. Gain of function mutations in this region lead to severe hyperinflammatory disorders 55. Such mutations abrogate autoinhibition by the C-terminal leucine rich region 60. p.R310X would eliminate this region from the protein. The other two ultra-rare variants, c.2309T>C (p.M770T) and c.1799A>G (p.E600G), map to the leucine-rich repeat region (LRR). Mutations in the LRR affecting the oligomerization interface were recently described in two patients with early-onset macrophage activation syndrome 61.

RAG1 codes for recombination activating gene 1, which is involved in antibody and T-cell receptor V(D)J recombination. RAG1 deficiency leads to abnormalities in T- and B-cell tolerance and immune dysregulation, leading to both an increased risk of infection and autoimmune problems 62, 63. Ultra-rare mutations were found in three patients, one of which, c.256_257delAA causes a frameshift in exon 2 (p.K86VfsX33). This variant has previously been reported in a heterozygous patient with adult-onset lymphopenia, and in a homozygous patient with severe combined immunodeficiency (SCID) 64.

PANS candidate genes that affect microglia function

Several of the PANS candidate genes that affect the peripheral immune system also disrupt microglia function. For example, Ppm1d null mice exposed to a hypobaric hypoxic environment showed an augmented release of inflammatory cytokines from activated microglia 65. In microglia derived from iPSCs, PLCG2 expression was found to mediate cell survival, phagocytosis, and processing of neuronal debris 66. Finally, Nlrc4 regulates apoptotic and pyroptotic microglial death following ischemic stroke 67, 68, and astrogliosis and microgliosis in a mouse model of neuroinflammation 69.

Additional support for an immune-related effect of a subgroup of PANS-associated candidate genes on microglia function comes from our analysis of a gene expression dataset in LPS-treated mice (GSE102482) 15. We found that Sgce and Plcg2 were the 2nd and 8th most downregulated transcripts, and Nlrc4 the 6th most upregulated transcript, in microglia derived from control and LPS-treated mice upon an analysis of a subset of 148 autism and pediatric immune disorder genes (Figure 2).

Figure 2.
Figure 2.

Heat map of LPS-mediated gene expression in microglia. Microarray gene expression data (GSE102482) from Greenhalgh et at. (reference 15) were analyzed to determine the expression pattern of a subset of 148 autism and pediatric immune disorder genes. The heat map shows the data obtained from RNA extracted from microglia grown on their own or co-cultured with peripheral macrophages. Arrows point to differentially expressed genes that are PANS candidates described in this report.

In addition to these PANS candidate genes, the expression of Sgce, which will be described in more detail in the next section, is induced in microglia following viral-mediated neuroinflammation in mice 70. Similarly, we previously found that Sgce expression increased significantly in microglia derived from a mouse model of Rett syndrome, in which innate immune pathways were the most enriched differentially expressed genes 71.

These findings support the idea that a subgroup of PANS candidate genes affect microglia function.

Neuronal PANS candidate genes associated with neurological and neurodevelopmental disorders

Six PANS candidate genes identified in this study, SHANK3, GRIN2A, SYNGAP1, CACNA1B, GABRG2, and SGCE, are primarily expressed in neurons and variants in these genes have been associated with ASD and other neurodevelopmental disorders. SHANK3, for example, codes for a scaffold protein that regulates the assembly of PSD-95 at glutamatergic excitatory synapses 72–75. It is among the most commonly mutated genes in ASD and other neurodevelopmental disorders 76–79. Of the 1003 genes in the Simons Foundation Autism Research Initiative (SFARI) database, SHANK3 has the second highest number of reports. Ultra-rare variants were found in three PANS patients (c.4622C>T, p.1541L; c.3637dupG, p.1213fsX68; c.4776dupC, p.T1593fsX86). Although SHANK3 mutations in ASD are scattered throughout the gene, the majority, including our cases, are found in exon 21, which codes for the proline-rich region (PRR) that binds to and draws other synaptic proteins to the post-synaptic density. ASD-associated variants in SHANK3 disturb mGluR-dependent synaptic plasticity 73.

Case 18 (c.3637dupG, p.1213fsX68) was diagnosed with Phelan-McDermid syndrome, which is usually caused by SHANK3 deletions, developed the sudden onset of severe OCD following bacterial infections. Case 19 (c.4776dupC, p.T1593fsX86) has a history ASD with minimal verbal ability since early childhood. She developed the sudden onset of OCD and aggression as a child that improved dramatically with IVIG, although the baseline ASD and poor verbal ability did not improve.

Our finding of co-morbid ASD and PANS in the SHANK3 cases is similar to observations made by Bey et al., who identified de novo SHANK3 variants in four girls with lifelong, stable developmental delay (DD) who developed subacute, severe psychiatric symptoms resembling PANS, that responded, with varying degrees of success, to immunotherapy 80. Similarly, in an analysis of 38 individuals with Phelan-McDermid Syndrome, acute regression triggered by infections, changes in hormonal status, and stressful life events were commonly observed, several of whom improved with IVIG 81.

These findings show that a subgroup of patients with SHANK3-associated ASD and developmental disorders have an underlying susceptibility to develop acute onset neuropsychiatric problems that have a neuroinflammatory component.

Four other PANS-associated neuronal candidate genes we identified, SYNGAP1, GRIN2A, GABRG2, and CACNA1B mutations have also been found in ASD, epilepsy, and IDD 77, 82–86. GRIN2A and SYNGAP1 bind to PSD-95. According to the SFARI database, SYNGAP1 has the ninth highest number of reports. It codes for a postsynaptic Ras GTPase activating protein that regulates developing excitatory synaptic structure and function 87. Case 8 has a nonsense mutation at SYNGAP1 codon 1179. Like the SHANK3 cases, she was diagnosed with ASD as a child, and developed acute onset OCD and food restrictions following a culture positive streptococcus pharyngitis.

GRIN2A codes for the glutamate ionotropic receptor NMDA type subunit 2A. Mutations have been found in a variety of neurodevelopmental disorders including ASD, epilepsy, and developmental disabilities 84, 88. The ultra-rare variant found in case 6 maps to a conserved region of the CTD domain, which is involved in mediating intracellular signaling 85. The CTD region interacts with the MAGUK (membrane-associated guanylate kinase) family of proteins that bind to PSD-95 and function as important modulators of synaptic plasticity 89. This subject has a history of dyslexia, ADHD, and emotional problems.

CACNA1B codes for the voltage-dependent N-type calcium channel subunit alpha-1B, a constituent of the Cav2.2 channel. It too is a regulator of synaptic function that acts at the presynaptic terminal to increase neurotransmitter release, which then influences postsynaptic dendritic spine function 90. In addition to having frequent infections and PANS, Case 3 was diagnosed with Hodgkin’s lymphoma, nodular sclerosis subtype. He was treated with ABVD, and subsequently, autologous hematological stem cell transplant (HSCT). It is interesting to note that Hodgkin’s lymphoma is often found in patients with autoimmune problems and is associated with abnormalities in IL-13 signaling, a cytokine produced by mast cells, eosinophils, nuocytes, and Th2 cells 92–94. This patient also has psoriasis, a Th17 associated autoimmune disorder 95, 96. This suggests the possibility that CACNA1B could have unrecognized effects on the immune system by disrupting IL-13 and Th17 signaling leading to PANS, psoriasis, and Hodgkin lymphoma. It is also interesting to note that his neuropsychiatric symptoms have temporarily disappeared following HSCT. However, the follow-up period has only been a few months, so it is too early to determine if the treatment has had a positive impact on his neuropsychiatric symptoms. Autologous HSCT is an emerging technology for treating severe autoimmune disorders 91. Given these observations, HSCT could prove to be an option for treating a small subgroup of chronic, refractory, severely impaired PANS patients.

GABRG2 codes for the gamma subunit of the GABA-A receptor, a ligand-gated chloride channel. It is one of the most mutated genes in febrile seizures and other forms of epilepsy 97, 98. We found a nonsense mutation, c.649C>T; p.Gln217X, in a child with severe PANS (case 5). This is the same mutation previously found in sleep-related epilepsy 99. Case 5 has a history of febrile seizures.

SGCE is a member of the sarcoglycan family of transmembrane proteins, a component of the dystrophin-associated glycoprotein complex (DGC). Studies carried out in knockout mice show that SGCE inhibits excitatory synapse formation, and that loss-of-function mutations lead to an increase in excitatory synapses 100. The DGC is involved in organizing aquaporin-4-containing protein complexes in glia that controls the formation of the glymphatic system. The glymphatic system clears waste from the brain, and impaired glymphatic drainage has been found in neuroinflammation and dementia 101–103. Ultra-rare mutations in SGCE were found in two unrelated subjects, cases 10 and 11.

Remarkably, SGCE, CACNA1B, and GRIN2A are well-known for causing Myoclonus-Dystonia (M-D), a hyperkinetic movement disorder, which is similar to tics, a diagnostic feature of PANDAS. SGCE, in fact, is the most commonly mutated gene in M-D, with more than one-third of cases having truncating mutations in exon 3, which contains the del150Iso in-frame mutation found in case 10 104–106. Interestingly, patients with myoclonus caused by SGCE mutations frequently have co-morbid psychiatric symptoms, including depression, anxiety, bipolar disorder, phobias, alcoholism, and OCD 106, symptoms that overlap with PANS. Similarly, GRIN2A and CACNA1B mutations have been found in dystonic and other rare movement disorders 85, 107–110.

These findings suggest that deleterious variants in these “neuronal” genes can result in a range of clinical phenotypes; M-D, ASD, developmental disabilities, epilepsy, and PANS, or PANS co-morbid with these neurodevelopmental problems. It is important to add, however, that case 7 with the PLCG2 ultra-rare variant c.617A>G, p.Y206F, as well as cases 12, 14, and 15, who have mutations in NLRC4 and RAG1, also had preexisting ASD prior to developing PANS. Thus, PANS/ASD co-morbidity is not restricted to cases with variants in genes typically associated with neurodevelopmental disorders. Other genetic factors causing the neurodevelopmental problems, however, cannot be ruled out at this time.

Connectivity Network

To assess potential functional connections between the PANS candidate genes, we generated a connectivity network to show the direct (solid lines) and indirect interactions (dotted lines) (Figure 3). Included in the network are two additional PANS candidate genes, MTHC2 and BID, identified by one of us (R.T.) by GWAS that will be described in a separate paper. Central to the network is the NF-κB complex transcriptional regulator, which is activated by a variety of immune, infectious, and non-immune (e.g., oxidative stress; toxins) stressors 111, 112. Inappropriate activation of NF-κB has been associated with inflammatory diseases 113. Directly connected to the NF-κB hub are the PANS candidate genes; PPM1D, PLCG2, NLRC4, RAG1, and BID, along with CHK2 and MTCH2, which bind to PPM1D and BID, respectively. This hub represents the set of PANS genes that likely to function through a disruption of peripheral and central innate immunity. The PANS candidate genes not directly connected to NF-κB expression are those that are primarily expressed in the brain and cause neurodevelopmental disorders (CACNA1B, SYNGAP1, GRIN2A, SGCE, GABRG2, and SHANK3).

Figure 3.
Figure 3.

Connectivity network. A connectivity network was generated for each candidate gene using IPA software. Two additional PANS candidate genes, MTHC2 and BID, identified by one of us (R.T.) are included. These will be described in a separate paper. Central to the network is the NF-κB complex transcriptional regulator hub, which connects to PPM1D, PLCG2, NLRC4, RAG1, BID, CHK2 and MTCH2. The PANS candidate genes not directly connected to NF-κB expression are those that are primarily expressed in the brain and cause neurodevelopmental disorders (CACNA1B, SYNGAP1, GRIN2A, SGCE, GABRG2, and SHANK3). See Supplemental Data for symbol key.

Interestingly, CaMKII, a biomarker from the Cunningham panel, is also centrally localized within the connectivity network and has a close relation to multiple candidate genes.

Tissue and Cell Expression Pattern of PANS Candidate Genes

To gain further insight into the mechanisms by which the PANS candidate genes lead to neuroinflammation, we examined their expression pattern using several gene expression resources, one of which is a single cell RNA-seq (scRNA-seq) database of white blood cells (WBCs)16. This database contains gene expression patterns in control samples (N=6) and hospitalized COVID-19 patients (N=7). The candidate genes that have established effects on peripheral immune function, PPM1D, CHK2, and RAG1, are expressed in multiple cell types, PLCG2 is primarily expressed in B-cells, and NLRC4 in monocytes and neutrophils (Figure S1). Interestingly, the expression of several genes was significantly affected in the COVID-19 patients. Most notably, a >100-fold increase in NLRC4 expression was found in developing neutrophils. This suggests that PANS-associated NLRC4 mutations could lead to a marked alteration in inflammasome function following infections. In addition, a >8-fold increase in CHK2 (also known as CHEK2) was found in interferon stimulated genes in T4 cells.

Although most of the “neuronal” PANS candidate genes are expressed at very low levels in WBCs, there are three notable exceptions. Most striking is GABRG2, which shows marginal expression in all WBCs except for T.gd cells (γδ T cells) in COVID-19 patients, where a >20-fold increase in expression was found compared with controls. γδ T cells form a minor population of WBCs, but they increase dramatically during infections and play a key role in autoimmunity and immune surveillance 114, 115. Perhaps more importantly from the perspective of PANS is the finding that γδ T cells are found in meninges where they secrete the proinflammatory cytokine IL-17a and participate in the development of anxiety-like behavior in mice 116.

SYNGAP1 is expressed in many WBC subtypes, especially T cells. Strikingly, like GABRG2, expression in γδ T cells increases nearly 4-fold in COVID-19 patients. And SHANK3 expression, while negligible in most WBCs, is abundant in a cluster consisting of two groups of cells labeled as stem cells and eosinophils.

These finding suggest that some neuronal PANS candidate genes that typically cause neurodevelopmental disorders have unanticipated effects on immune function and their expression is extremely responsive to an infectious disease stressor. Parenthetically, these findings show that it will be important to monitor the potential impact of SARS-CoV-2 as an infectious disease inducer of PANS.

We next analyzed the cell and tissue expression pattern of each of the PANS candidate genes in normal human tissues using the GTEx dataset (Figure S2). The gene expression patterns, based on bulk RNA-seq, generally conform to the functional groups described above and the connectivity network. The genes affecting peripheral immunity that are connected to the NF-κB hub are expressed primarily in blood and EB-transformed lymphoblasts, and less so in the brain, while the genes associated with neurodevelopmental disorders show the opposite pattern. PPM1D, RAG1, and SGCE are highly expressed in both.

To gain further insight into the expression of the PANS candidate genes in the nervous system, we examined the cell type expression pattern in adolescent and fetal mouse brains. One of the more striking observations in the adolescent brain is the relatively high level of Chk2 expression in ependymal cells compared with all other brain cell types (Figure 4; see Table S1 for abbreviation key). Ependymal cells line the ventricles and spinal canal and play an important role in the production of CSF 117. As part of the choroid plexus, ependymal cells regulate the blood-CSF barrier 118. The choroid plexus plays a key role in neuroinflammatory and neurodegenerative disorders and serves as a nexus for peripheral T-cells that can infiltrate the brain, as well as access, when damaged, to proinflammatory cytokines, complement, and autoantibodies from the circulation to the brain parenchyma 119–121. Ppm1d, Sgce, Plcg2, Syngap1, and Shank3 are also expressed in these cells, suggesting that their mutated versions could disturb the blood-CSF barrier.

Figure 4.
Figure 4.

Single cell RNA-seq expression pattern of each PANS candidate gene in mouse adolescent brains (mouse brain atlas; see Web Resources)

Another interesting finding in adolescent nervous system is the relatively high level of expression of Ppm1d, Syngap1, Cacna1b, and Sgce throughout the enteric nervous system. The potential implications of this expression pattern will be described in the discussion section.

We also examined the single cell gene expression pattern of the PANS candidate genes in the developing mouse brain, considering the fact that several cause neurodevelopmental disorders (Figure S3). One of the more interesting findings is the expression of Shank3, which, as expected, was diffusely expressed throughout the brain in both glutamatergic neurons and GABAergic interneurons. However, the highest levels were seen in the choroid plexus and cerebral vasculature. In fact, all of the PANS candidate genes, with the exception of RAG1 are expressed in fetal choroid plexus, cerebral vasculature, and pericytes, with Sgce, Chk2 and Ppm1d, along with Shank3, being most prominent. This is similar to the single cell expression pattern seen in adolescent brains (Figure 4), reinforcing the idea that disruption of the blood-CSF barrier and/or the BBB is playing a role in the emergence of PANS.

Discussion

Genetic contributions to disease can be divided into common variants that have relatively small biological effects, which are generally identified by large-scale GWAS, and high impact, biologically significant ultra-rare variants. So far, no reports have been published in which common variants were identified, although there is a small, unpublished study derived from a direct-to-consumer DNA testing service in which five SNPs associated with PANS and PANDAS were found (see Web Resources), two of which occur in credible candidate genes (rs5029936 in TNFAIP3; rs76298532 in MCPH1).

In the current study, we searched for ultra-rare variants in PANS patients using next generation sequencing. For the European cohort, cases were selected for their severity. The index case was a teenage girl with severe, chronic PANS who was found, along with her affected brother, to have an ultra-rare PPM1D mutation (c.131C>G; p.S44W) (Figure 1). This mutation is upstream of the phosphatase domain and its effect on PPM1D catalytic function is not immediately clear. However, the nearby serine amino acids S40 and S46 could be playing a role the development of PANS in this family. These are substrates for the serine kinases DYRK1A and HIPK2, which cause IDD, ASD, and abnormal feeding behavior when mutated 122–124. DYRK1A also has important effects on innate immunity by regulating the balance between Th17 and T regulatory (Treg) cells, T cell subsets involved in the development of autoimmune diseases and inflammation 125–129. Interestingly, Th17 mediates the effects of Streptococcus on neuroinflammation in a mouse model of PANDAS by causing a breach in the BBB, with subsequent brain infiltration of Th17 lymphocytes 125, 130–132. HIPK2 regulates PPM1D protein levels by inducing its degradation in DNA-damaged cells, triggering activation of the DNA repair pathway 133. HIPK2 expression increases in LPS-stimulated macrophages, and its knockdown attenuates the expression of inflammatory cytokines 134, 135. S46 is also a HIPK2 substrate. Thus, an effect of S44W on immune regulation could be secondary to altered interactions between DYRK1A and HIPK2 with PPM1D.

Following the discovery of this variant, we identified an additional eight other severely affected patients through a PANS/PANDAS advocacy group that primarily operates in the European Union. WGS was carried out, which resulted in the identification of ultra-rare variants in plausible candidate genes in every patient in the European cohort. Although there is a clear ascertainment bias for these participants, the findings of ultra-rare variants in the same genes and other plausible candidates in an unselected, modestly sized population in the United States cohort suggest that severe PANS is often caused by biologically powerful ultra-rare genetic variants. The condition can be viewed as a heterogenous genetically dominant disorder, albeit, with reduced penetrance. Evidence that penetrance is not 100% is seen in several families in whom transmission occurred from a carrier parent who do not have neuropsychiatric problems typical of PANS. The PPM1D variant, for example, was inherited from an asymptomatic father who has a family history of autoimmune disorders, In addition, two siblings of case 10 (SGCE (del150 Iso; c.450_452) also inherited the variant. One has asthma, allergies, and contact dermatitis, but no neuropsychiatric problems; The other has similar atopic problems. Although he does not have PANS, he has developed debilitating, recurrent cluster-type headaches. Whether the headaches are a manifestation of neuroinflammation, or vasculitis is not known.

Finally, case 9 (NLRC4 c.772T>C; p.C258R), inherited the mutation from a mother who has with a history of psoriasis and arthritis. She was diagnosed with focal epilepsy as an adult but has no history of PANS. A younger sibling with the same variant has a history suggestive of PANS but has not yet been clinically ascertained.

The lack of complete penetrance is consistent with a small monozygotic twin study in PANDAS that showed a range of different phenotypes, including complete discordance 136. Similarly, the MZ twin concordance rate in autoimmune disorders ranges from approximately 20%-70% depending on the condition 137.

This suggests that environmental factors are playing a role in PANS. In the case of the generation divide between carrier parents and their affected children, changes in the prevalence of certain strains of bacteria and antigenic shifts in viruses implicated as PANS triggers, could account for their different clinical outcomes. Borrelia burgdorferi, which causes Lyme disease, is an example of an infectious disease that has markedly increased in prevalence in the past 30 years, while antigenic shifts in viruses that cause influenza or common cold are examples of infectious diseases that are subject to rapid genetic changes. In addition, the current generation of youth might be exposed to non-infectious environmental triggers that were not as prevalent in past generations. Although unaffected carrier parents might be exposed to the same infectious agents or non-infectious stressors that are currently triggering PANS flareups in their children, age-related differences in the blood-CSF barrier or BBB could make the adult brain less susceptible 138. Genetic background and stochastic T cell receptor and IgG gene rearrangement could also explain reduced penetrance in families, and discordance in MZ twins.

The candidate genes identified in this study can be broadly separated into those that have established effects on peripheral innate and adaptive immunity, and those that affect synaptic function in particular the PSD-95 complex. However, this peripheral vs central dichotomy, which could potentially explain the presence or absence of immune markers and response to immunomodulators, is an oversimplification. First, as noted earlier, several PANS candidate genes that have effects on peripheral innate immunity, such as PPM1D, PLCG2, and NLRC4, also affect microglia function and are differentially expressed in those cells following an immune challenge. Second, patients with mutations in genes that function as synaptic regulators, such as SHANK3, can respond to IVIG, as shown by Bey et al 80. Similarly, our cases with ultra-rare variants in SHANK3, CACNA1B, SGCE and GABRG2 also responded to IVIG. Third, as shown in Figure S1, neuronal genes like SHANK3, GABRG2 and SYNGAP1 show expression patterns that strongly support an adverse effect on immune function, in particular γδ T-cells, based on their markedly altered expression during upon an infectious disease challenge. Fourth, some of the neuronal PANS candidate genes that have effects on synaptic function, such as SHANK3, SGCE, CHK2, and PPM1D, are also expressed in the choroid plexus and brain vascular endothelium, which could potentially connect peripheral inflammation with neuroinflammation through disruption of the brain/CSF barrier and BBB caused by mutations in these genes. SHANK3 is a cytoskeletal protein that regulates glutamatergic synaptogenesis, but it can also function as a scaffolding protein in epithelial cells139. In addition, PPM1D has been found to regulate BBB function and neuroinflammation in a co-culture of human brain-microvascular endothelial cells and human astrocytes treated with LPS 140.

Expression of PANS candidate genes in the choroid plexus and vascular endothelium during fetal development is also interesting when considering the phenomenon known as maternal immune activation (MIA), a proinflammatory state in pregnancy triggered by infection, maternal autoimmune disorders, and non-infectious peripheral inflammation141, 142. The fetal brain is vulnerable to changes in the maternal/fetal environment, such as MIA 141–143, which has been shown in animal models to adversely affect brain development, leading to behaviors and learning difficulties similar to those seen in patients with ASD and schizophrenia 144–152. Consequently, it is conceivable that the pathophysiological process that leads to the development of PANS and co-morbid neurodevelopmental disorders could begin during fetal life in some patients and genetic subgroups.

An effect on the choroid plexus and vasculature endothelium (and γδ T cells) could also explain the response to IVIG in those patients harboring mutations in the “neuronal” subgroup of candidate genes. IVIG can reduce neuroinflammation by affecting T-cell/microglia crosstalk, reducing levels of proinflammatory cytokines, blocking Fcγ receptors, inhibiting complement, and repairing disrupted brain-CSF barriers 153–156.

While extra-neuronal effects of synaptic proteins could have an impact on the development of PANS, their effects on synaptogenesis in the development of PANS should also be considered. One possible mechanism is a defect in PSD-95 assembly and glutamate receptor function leading to abnormal synaptic remodeling. This could trigger over-activation of microglia, which in turn would release proinflammatory cytokines, complement, prostaglandins, proteinases, and reactive oxygen species, causing neuroinflammation. An extension of this model is that a similar overactivation of microglia could be driven by a primary, intrinsic defect caused by PANS candidate genes that are highly expressed in microglia, but not neurons (e.g., PLCG2, NLRC4). This is consistent with our finding that Plcg2, Sgce, and Nlrc4 are differentially expressed in LPS-treated microglia (Figure 2). Non-neuronal stimuli that might induce microglia overactivation in PANS is open to speculation, but could include oxidative stress, environmental toxins, and peripheral infection/inflammation.

Finally, it is interesting to consider the implications of the finding that several PANS candidate genes are also mutated in D-M, ASD, and other neurodevelopmental disorders. PANS is occurring as an independent phenotype in some of our cases, and as a comorbid trait in others. These comorbid cases are like the SHANK3-mutated patients reported by Bey et al. 80. Similarly, Jones et al., described eight children with ASD and other neurodevelopmental disorders, with a strong family history of maternal autoimmune thyroid disorders, who presented with infection-induced, abrupt onset of neuropsychiatric symptoms, primarily OCD and tics, along with autistic or global regression157. Overall, comorbid ASD and other neuropsychiatric disorders were found in nine cases in our study, not including cases 1 and 2 who were typically developing prior to the onset of PANS and the development of chronic symptoms (Table 2)

The development of either PANS, a neurodevelopmental disorder, or PANS comorbid with a neurodevelopmental disorder, could be due to subtle mutation-specific effects on neuronal or immune function, environmental factors (e.g., MIA), or genetic background. A genetic connection between PANS, D-M, ASD, and other neurodevelopmental disorders also supports the idea that an inflammatory component is involved in the pathogenesis of subgroups of patients with schizophrenia and ASD, as suggested by numerous genetic and molecular studies 157–164 At the very least, an inflammatory component leading to the abrupt onset of PANS superimposed on a chronic neurodevelopmental disorder is a real phenomenon that needs to be recognized by the medical community because immunological therapies like IVIG could be very helpful.

Expression of PANS/PANDAS candidate genes in the enteric nervous system

Another aspect of our genetic analysis was the finding that many of the candidate genes we identified are expressed in enteric neurons, which could perhaps explain the abdominal complaints experienced by PANS patients 3. In addition, enteric expression could be playing a direct role in the development of PANS in some genetic subgroups. For example, cholinergic fibers come in close contact with macrophages, plasma cells, and lymphocytes located in the intestinal mucosa, and gut-associated lymphoid tissue 165. In addition, patients with PANS/PANDAS have been found to have differences in the gut microbiome compared with controls 166, 167, and an increase in gut-derived LPS and markers of oxidative stress 168. More specific to the candidate genes we identified, several have established effects on the gut. PPM1D, for example, has been found to have a protective effect on oxidation stress-induced gut permeability 165. In addition, Shank3 knockout mice have an altered microbiota composition, an increase in LPS levels in the liver, and altered gut permeability 169, 170. Furthermore, variants in and altered gut permeability NLRC4 have been implicated in inflammatory bowel disease 171, 172.

Overall, the expression of PANS candidate genes in the enteric nervous system fits into the emerging idea that disruption of the gut-brain connection and the gut microbiome are involved in the pathogenesis of ASD, neurodegeneration, neuropsychiatric disorders, autoimmune disorders, and PANS 173–177.

In summary, we identified ultra-rare genetic variants in PANS patients that appear to function at multiple levels of the neuroinflammatory circuit, including peripheral and central innate immunity, synaptogenesis, the blood-CSF barrier, and perhaps the enteric nervous system. Dissecting the molecular and cellular pathogenesis of the PANS candidate variants will require an analysis in mouse models, as well as patient-specific induced pluripotent stem cells, from which cells of importance in the development of PANS, such as neurons, microglia, astrocytes, neuronal epithelium, vascular endothelium, and gut organoids can be derived.

Data Availability

genotyping data are available from the co-first authors and the senior author

Supplemental Information

Supplemental data include 3 figures and 1 table, Supplemental Note: Case Reports

Declaration of Interests

The authors declare no competing interests

Acknowledgments

The authors want to thank EXPAND for directing researchers to PANS cases throughout the European Union, and Erika Pedrosa for copy editing the manuscript. HML is supported by the National Institute of Child Health and Human Development NIH/NICHD; P30 HD071593 to the Albert Einstein College of Medicine’s Rose F. Kennedy Intellectual and Developmental Disabilities Research Center. The Lachman lab also receives support from the Janice C. Blanchard Family Fund. P.J. van der Spek is supported by EU H2020 grants, an ImmunAID grant (ID: 7792950), and a MOODSTRATIFICATION grant (ID: 754740). The Bioinformatics infrastructure and team is supported by grants from KWF, NWO/ZonMW and the Dutch Heart foundation through the BDVA initiated H2020 Bigmedilytics program on Personalized Medicine. Neither the authors nor their academic institutions received payment or services from a third party for any aspect of the submitted work including the study design and manuscript preparation.

The authors dedicate this paper to Dr. Paul Janssen whose ideas about the role of the immune system in tics and psychosis help form the framework for this research project, and to participating families for their courage and support.

References

  1. 1.↵
    Swedo, S.E., Leonard, H.L., Mittleman, B.B., Allen, A.J., Rapoport, J.L., Dow, S.P., Kanter, M.E., Chapman, F., Zabriskie, J. (1997). Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am. J. Psychiatry 154, 110–112.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Calaprice, D., Tona, J., Parker-Athill, E.C., Murphy, T.K. (2017). A Survey of Pediatric Acute-Onset Neuropsychiatric Syndrome Characteristics and Course. J. Child Adolesc. Psychopharmacol. 27, 607–618.
    OpenUrl
  3. 3.↵
    Chang, K., Frankovich, J., Cooperstock, M., Cunningham, M.W., Latimer, M.E., Murphy, T.K., Pasternack, M., Thienemann, M., Williams, K., Walter, J. et al. (2015). Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. J. Child Adolesc. Psychopharmacol. 25, 3–13.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Wilbur, C., Bitnun, A., Kronenberg, S., Laxer, R.M., Levy, D.M., Logan, W.J., Shouldice, M., Yeh, E.A. (2019). PANDAS/PANS in childhood: Controversies and evidence. Paediatr. Child. Health. 24, 85–91.
    OpenUrl
  5. 5.
    Chiarello, F., Spitoni, S., Hollander, E., Matucci Cerinic, M., Pallanti, S. (2017). An expert opinion on PANDAS/PANS: highlights and controversies. Int. J. Psychiatry Clin. Pract. 21, 91–98.
    OpenUrl
  6. 6.↵
    Gilbert, D.L. (2019). Inflammation in Tic Disorders and Obsessive-Compulsive Disorder: Are PANS and PANDAS a Path Forward? J. Child Neurol. 34, 598–611.
    OpenUrl
  7. 7.↵
    Zheng, J., Frankovich, J., McKenna, E.S., Rowe, N.C., MacEachern, S.J., Ng, N.N., Tam, L.T., Moon, P.K., Gao, J., Thienemann, M. et al. (2020). Association of Pediatric Acute-Onset Neuropsychiatric Syndrome With Microstructural Differences in Brain Regions Detected via Diffusion-Weighted Magnetic Resonance Imaging. JAMA Netw. Open 3, e204063.
    OpenUrl
  8. 8.↵
    Vitaliti, G., Tabatabaie, O., Matin, N., Ledda, C., Pavone, P., Lubrano, R., Serra, A., Di Mauro, P., Cocuzza, S., Falsaperla, R. (2015). The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data. Hum. Vaccin Immunother. 11, 2749–2763.
    OpenUrl
  9. 9.↵
    Melamed, I., Kobayashi, R.H., O’Connor, M., Kobayashi, A.L., Schechterman, A., Heffron, M., Canterberry, S., Miranda, H., Rashid, N. (2021). Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome. J. Child Adolesc. Psychopharmacol. 31, 118–128.
    OpenUrl
  10. 10.↵
    Frankovich, J., Leibold, C.M., Farmer, C., Sainani, K., Kamalani, G., Farhadian, B., Willett, T., Park, J.M., Sidell, D., Ahmed, S. et al. (2018). The Burden of Caring for a Child or Adolescent With Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): An Observational Longitudinal Study. J. Clin. Psychiatry 80, 17m12091. doi: 10.4088/JCP.17m12091.
    OpenUrlCrossRef
  11. 11.↵
    Gromark, C., Hesselmark, E., Djupedal, I.G., Silverberg, M., Horne, A., Harris, R.A., Serlachius, E., Mataix-Cols, D. (2021). A Two-to-Five Year Follow-Up of a Pediatric Acute-Onset Neuropsychiatric Syndrome Cohort. Child Psychiatry Hum. Dev., 1–11.
  12. 12.↵
    Frankovich, J., Thienemann, M., Rana, S., Chang, K. (2015). Five youth with pediatric acute-onset neuropsychiatric syndrome of differing etiologies. J. Child Adolesc. Psychopharmacol. 25, 31–37.
    OpenUrl
  13. 13.↵
    Erikson, G.A., Bodian, D.L., Rueda, M., et al. (2016) Whole-genome sequencing of a healthy aging cohort. Cell. 2016;165: 1002–1011.
    OpenUrlCrossRefPubMed
  14. 14.↵
    Drmanac, R., Sparks, A.B., Callow, M.J., Halpern, A.L., Burns, N.L., Kermani, B.G., Carnevali, P., Nazarenko, I., Nilsen, G.B., Yeung, G. et al. (2010). Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327, 78–81.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Greenhalgh, A.D., Zarruk, J.G., Healy, L.M., Baskar Jesudasan, S.J., Jhelum, P., Salmon, C.K., Formanek, A., Russo, M.V., Antel, J.P., McGavern, D.B. et al. (2018). Peripherally derived macrophages modulate microglial function to reduce inflammation after CNS injury. PLoS Biol. 16, e2005264.
    OpenUrlCrossRef
  16. 16.↵
    Wilk, A.J., Rustagi, A., Zhao, N.Q., Roque, J., Martinez-Colon, G.J., McKechnie, J.L., Ivison, G.T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020). A single-cell atlas of the peripheral immune response to severe COVID-1. Nat Med. Jul; 26(7), 1070–1076.
    OpenUrl
  17. 17.↵
    GTEx Consortium. (2020). The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science Sep 11;369(6509):1318–1330.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    Zeisel, A., Hochgerner, H., Lönnerberg, P., Johnsson, A., Memic, F., van der Zwan, J., Häring, M., Braun, E., Borm, L.E., La Manno, G. et al. (2018). Molecular Architecture of the Mouse Nervous System. Cell 174, 999–1014.e22.
    OpenUrlCrossRefPubMed
  19. 19.↵
    La Manno, G., Siletti, K., Furlan, A., Gyllborg, D., Vinsland, E., Langseth, C.M., Khven, I., Johnsson, A., Nilsson, M., Lönnerberg, P., et al. Molecular architecture of the developing mouse brain. bioRxiv (2020)
  20. 20.↵
    Gagliano, A., Galati, C., Ingrassia, M., Ciuffo, M., Alquino, M.A., Tanca, M.G., Carucci, S., Zuddas, A., Grossi, E. (2020). Pediatric Acute-Onset Neuropsychiatric Syndrome: A Data Mining Approach to a Very Specific Constellation of Clinical Variables. J Child Adolesc Psychopharmacol. Oct;30(8):495–511.
    OpenUrl
  21. 21.↵
    Fernell, E., Sundin, M., Fasth, A., Dinkler, L., Galazka, M., Gillberg, C., Johnson, M. (2021). Paediatric Acute onset Neuropsychiatric Syndrome: Exploratory study finds no evidence of HLA class II association but high rate of autoimmunity in first-degree relatives. Acta Paediatr.
  22. 22.↵
    Burgess, D.J. (2021). The TOPMed genomic resource for human health. Nat. Rev. Genet. Apr;22(4):200. doi: 10.1038/s41576-021-00343-x.
    OpenUrlCrossRef
  23. 23.↵
    Yoda, A., Xu, X.Z., Onishi, N., Toyoshima, K., Fujimoto, H., Kato, N., Oishi, I., Kondo, T., Minami, Y. (2006). Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1. J. Biol. Chem. 281, 24847–24862.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    Cardoso, M., Paulo, P., Maia, S., Teixeira, M.R. (2016). Truncating and missense PPM1D mutations in early-onset and/or familial/hereditary prostate cancer patients. Genes Chromosomes Cancer 55, 954–961.
    OpenUrl
  25. 25.
    Swisher, E.M., Harrell, M.I., Norquist, B.M., Walsh, T., Brady, M., Lee, M., Hershberg, R., Kalli, K.R., Lankes, H., Konnick, E.Q. et al. (2016). Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. JAMA Oncol. 2, 370–372.
    OpenUrlPubMed
  26. 26.↵
    Alzahrani, A.S., Murugan, A.K., Qasem, E., Alswailem, M.M., AlGhamdi, B., Moria, Y., Al-Hindi, H. (2018). Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer. Endocrine.
  27. 27.↵
    Jansen, S., Geuer, S., Pfundt, R., Brough, R., Ghongane, P., Herkert, J.C., Marco, E.J., Willemsen, M.H., Kleefstra, T., Hannibal, M. et al. (2017). De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome. Am. J. Hum. Genet. 100, 650–658.
    OpenUrl
  28. 28.
    Lelieveld, S.H., Reijnders, M.R., Pfundt, R., Yntema, H.G., Kamsteeg, E.J., de Vries, P., de Vries, B.B., Willemsen, M.H., Kleefstra, T., Lohner, K. et al. (2016). Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. Nat. Neurosci. 19, 1194–1196.
    OpenUrlCrossRefPubMed
  29. 29.
    Porrmann, J., Rump, A., Hackmann, K., Di Donato, N., Kahlert, A.K., Wagner, J., Jahn, A., Eger, I., Flury, M., Schrock, E. et al. (2018). Novel truncating PPM1D mutation in a patient with intellectual disability. Eur. J. Med. Genet.
  30. 30.
    Deciphering Developmental Disorders Study. (2017). Prevalence and architecture of de novo mutations in developmental disorders. Nature 542, 433–438.
    OpenUrlCrossRefPubMed
  31. 31.↵
    Porrmann, J., Rump, A., Hackmann, K., Di Donato, N., Kahlert, A.K., Wagner, J., Jahn, A., Eger, I., Flury, M., Schrock, E. et al. (2019). Novel truncating PPM1D mutation in a patient with intellectual disability. Eur. J. Med. Genet. 62, 70–72.
    OpenUrl
  32. 32.↵
    Sun, B., Hu, X., Liu, G., Ma, B., Xu, Y., Yang, T., Shi, J., Yang, F., Li, H., Zhang, L. et al. (2014). Phosphatase Wip1 negatively regulates neutrophil migration and inflammation. J. Immunol. 192, 1184–1195.
    OpenUrlAbstract/FREE Full Text
  33. 33.
    Yi, W., Hu, X., Chen, Z., Liu, L., Tian, Y., Chen, H., Cong, Y.S., Yang, F., Zhang, L., Rudolph, K.L. et al. (2015). Phosphatase Wip1 controls antigen-independent B-cell development in a p53-dependent manner. Blood 126, 620–628.
    OpenUrlAbstract/FREE Full Text
  34. 34.
    Liu, G., Hu, X., Sun, B., Yang, T., Shi, J., Zhang, L., Zhao, Y. (2013). Phosphatase Wip1 negatively regulates neutrophil development through p38 MAPK-STAT1. Blood 121, 519–529.
    OpenUrlAbstract/FREE Full Text
  35. 35.
    Tang, Y., Pan, B., Zhou, X., Xiong, K., Gao, Q., Huang, L., Xia, Y., Shen, M., Yang, S., Liu, H. et al. (2017). Wip1-dependent modulation of macrophage migration and phagocytosis. Redox Biol. 13, 665–673.
    OpenUrl
  36. 36.↵
    Brichkina, A., Bulavin, D.V. (2012). WIP-ing out atherosclerosis with autophagy. Autophagy 8, 1545–1547.
    OpenUrlCrossRefPubMed
  37. 37.↵
    Zhang, Q., Zhang, C., Chang, F., Liang, K., Yin, X., Li, X., Zhao, K., Niu, Q., Tian, Z. (2016). Wip 1 inhibits intestinal inflammation in inflammatory bowel disease. Cell. Immunol. 310, 63–70.
    OpenUrlPubMed
  38. 38.↵
    Dudgeon, C., Shreeram, S., Tanoue, K., Mazur, S.J., Sayadi, A., Robinson, R.C., Appella, E., Bulavin, D.V. (2013). Genetic variants and mutations of PPM1D control the response to DNA damage. Cell. Cycle 12, 2656–2664.
    OpenUrl
  39. 39.↵
    Kleiblova, P., Stolarova, L., Krizova, K., Lhota, F., Hojny, J., Zemankova, P., Havranek, O., Vocka, M., Cerna, M., Lhotova, K. et al. (2019). Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Int. J. Cancer 145, 1782–1797.
    OpenUrl
  40. 40.↵
    Stolarova, L., Kleiblova, P., Janatova, M., Soukupova, J., Zemankova, P., Macurek, L., Kleibl, Z. (2020). CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate. Cells 9, 2675. doi: 10.3390/cells9122675.
    OpenUrlCrossRef
  41. 41.↵
    Helgeland, H., Gabrielsen, I., Akselsen, H., Sundaram, A.Y.M., Flåm, S.T., Lie, B.A. (2020). Transcriptome profiling of human thymic CD4+ and CD8+ T cells compared to primary peripheral T cells. BMC Genomics 21, 350-020-6755-1.
  42. 42.↵
    Davari, K., Frankenberger, S., Schmidt, A., Tomi, N.S., Jungnickel, B. (2014). Checkpoint kinase 2 is required for efficient immunoglobulin diversification. Cell. Cycle 13, 3659–3669.
    OpenUrl
  43. 43.↵
    Maffucci, P., Chavez, J., Jurkiw, T.J., O’Brien, P.J., Abbott, J.K., Reynolds, P.R., Worth, A., Notarangelo, L.D., Felgentreff, K., Cortes, P. et al. (2018). Biallelic mutations in DNA ligase 1 underlie a spectrum of immune deficiencies. J. Clin. Invest. 128, 5489–5504.
    OpenUrl
  44. 44.
    Chen, M.Y., Hsu, W.C., Hsu, S.C., Yang, Y.S., Chuang, T.H., Lin, W.J., Tan, T.H., Su, Y.W. (2019). PP4 deficiency leads to DNA replication stress that impairs immunoglobulin class switch efficiency. Cell Death Differ. 26, 1221–1234.
    OpenUrl
  45. 45.↵
    Dujka, M.E., Puebla-Osorio, N., Tavana, O., Sang, M., Zhu, C. (2010). ATM and p53 are essential in the cell-cycle containment of DNA breaks during V(D)J recombination in vivo. Oncogene 29, 957–965.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    Martín-Nalda, A., Fortuny, C., Rey, L., Bunney, T.D., Alsina, L., Esteve-Solé, A., Bull, D., Anton, M.C., Basagaña, M., Casals, F. et al. (2020). Severe Autoinflammatory Manifestations and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations. J. Clin. Immunol. 40, 987–1000.
    OpenUrl
  47. 47.
    Zhou, Q., Lee, G.S., Brady, J., Datta, S., Katan, M., Sheikh, A., Martins, M.S., Bunney, T.D., Santich, B.H., Moir, S. et al. (2012). A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am. J. Hum. Genet. 91, 713–720.
    OpenUrlCrossRefPubMed
  48. 48.
    Ombrello, M.J., Remmers, E.F., Sun, G., Freeman, A.F., Datta, S., Torabi-Parizi, P., Subramanian, N., Bunney, T.D., Baxendale, R.W., Martins, M.S. et al. (2012). Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N. Engl. J. Med. 366, 330–338.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    Yu, P., Constien, R., Dear, N., Katan, M., Hanke, P., Bunney, T.D., Kunder, S., Quintanilla-Martinez, L., Huffstadt, U., Schröder, A. et al. (2005). Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+ entry. Immunity 22, 451–465.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    Novice, T., Kariminia, A., Del Bel, K.L., Lu, H., Sharma, M., Lim, C.J., Read, J., Lugt, M.V., Hannibal, M.C., O’Dwyer, D. et al. (2020). A Germline Mutation in the C2 Domain of PLCγ2 Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases. J. Clin. Immunol. 40, 267–276.
    OpenUrl
  51. 51.↵
    Alehashemi, S., Goldbach-Mansky, R. (2020). Human Autoinflammatory Diseases Mediated by NLRP3-, Pyrin-, NLRP1-, and NLRC4-Inflammasome Dysregulation Updates on Diagnosis, Treatment, and the Respective Roles of IL-1 and IL-18. Front. Immunol. 11, 1840.
    OpenUrlCrossRef
  52. 52.
    Kay, C., Wang, R., Kirkby, M., Man, S.M. (2020). Molecular mechanisms activating the NAIP-NLRC4 inflammasome: Implications in infectious disease, autoinflammation, and cancer. Immunol. Rev. 297, 67–82.
    OpenUrl
  53. 53.
    Andrade, W.A., Zamboni, D.S. (2020). NLRC4 biology in immunity and inflammation. J. Leukoc. Biol. 108, 1117–1127.
    OpenUrl
  54. 54.
    Iqubal, A., Ahmed, M., Ahmad, S., Sahoo, C.R., Iqubal, M.K., Haque, S.E. (2020). Environmental neurotoxic pollutants: review. Environ. Sci. Pollut. Res. Int. 27, 41175–41198.
    OpenUrl
  55. 55.↵
    Liang, J., Alfano, D.N., Squires, J.E., Riley, M.M., Parks, W.T., Kofler, J., El-Gharbawy, A., Madan-Kheterpal, S., Acquaro, R., Picarsic, J. (2017). Novel NLRC4 Mutation Causes a Syndrome of Perinatal Autoinflammation With Hemophagocytic Lymphohistiocytosis, Hepatosplenomegaly, Fetal Thrombotic Vasculopathy, and Congenital Anemia and Ascites. Pediatr. Dev. Pathol. 20, 498–505.
    OpenUrl
  56. 56.↵
    Romberg, N., Vogel, T.P., Canna, S.W. (2017). NLRC4 inflammasomopathies. Curr. Opin. Allergy Clin. Immunol. 17, 398–404.
    OpenUrlCrossRef
  57. 57.↵
    Sundaram, B., Kanneganti, T.D. (2021). Advances in Understanding Activation and Function of the NLRC4 Inflammasome. Int. J. Mol. Sci. 22, 1048. doi: 10.3390/ijms22031048.
    OpenUrlCrossRef
  58. 58.↵
    Ip, W.K., Medzhitov, R. (2015). Macrophages monitor tissue osmolarity and induce inflammatory response through NLRP3 and NLRC4 inflammasome activation. Nat. Commun. 6, 6931.
    OpenUrlCrossRefPubMed
  59. 59.↵
    Sandall, C.F., Ziehr, B.K., MacDonald, J.A. (2020). ATP-Binding and Hydrolysis in Inflammasome Activation. Molecules 25, 4572. doi: 10.3390/molecules25194572.
    OpenUrlCrossRef
  60. 60.↵
    Hu, Z., Yan, C., Liu, P., Huang, Z., Ma, R., Zhang, C., Wang, R., Zhang, Y., Martinon, F., Miao, D. et al. (2013). Crystal structure of NLRC4 reveals its autoinhibition mechanism. Science 341, 172–175.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    Moghaddas, F., Zeng, P., Zhang, Y., Schützle, H., Brenner, S., Hofmann, S.R., Berner, R., Zhao, Y., Lu, B., Chen, X. et al. (2018). Autoinflammatory mutation in NLRC4 reveals a leucine-rich repeat (LRR)-LRR oligomerization interface. J. Allergy Clin. Immunol. 142, 1956–1967.e6.
    OpenUrl
  62. 62.↵
    Delmonte, O.M., Villa, A., Notarangelo, L.D. (2020). Immune dysregulation in patients with RAG deficiency and other forms of combined immune deficiency. Blood 135, 610–619.
    OpenUrl
  63. 63.↵
    Erman, B., Çipe, F. (2020). Genetic Screening of the Patients with Primary Immunodeficiency by Whole-Exome Sequencing. Pediatr Allergy Immunol Pulmonol Mar;33(1):19–24.
    OpenUrl
  64. 64.↵
    Abraham, R.S., Recher, M., Giliani, S., Walter, J.E., Lee, Y.N., Frugoni, F., Maddox, D.E., Kirmani, S., Notarangelo, L.D. (2013). Adult-onset manifestation of idiopathic T-cell lymphopenia due to a heterozygous RAG1 mutation. J. Allergy Clin. Immunol. 131, 1421–1423.
    OpenUrl
  65. 65.↵
    Li, D., Zhang, L., Huang, X., Liu, L., He, Y., Xu, L., Zhang, Y., Zhao, T., Wu, L., Zhao, Y. et al. (2017). WIP1 Phosphatase Plays a Critical Neuroprotective Role in Brain Injury Induced by High-Altitude Hypoxic Inflammation. Neurosci. Bull. 33, 292–298.
    OpenUrlPubMed
  66. 66.↵
    Andreone, B.J., Przybyla, L., Llapashtica, C., Rana, A., Davis, S.S., van Lengerich, B., Lin, K., Shi, J., Mei, Y., Astarita, G. et al. (2020). Alzheimer’s-associated PLCγ2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nat. Neurosci. 23, 927–938.
    OpenUrl
  67. 67.↵
    Poh, L., Kang, S.W., Baik, S.H., Ng, G.Y.Q., She, D.T., Balaganapathy, P., Dheen, S.T., Magnus, T., Gelderblom, M., Sobey, C.G. et al. (2019). Evidence that NLRC4 inflammasome mediates apoptotic and pyroptotic microglial death following ischemic stroke. Brain Behav. Immun. 75, 34–47.
    OpenUrlCrossRef
  68. 68.↵
    Bergsbaken, T., Fink, S.L., Cookson, B.T. (2009). Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 7, 99–109.
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.↵
    Freeman, L., Guo, H., David, C.N., Brickey, W.J., Jha, S., Ting, J.P. (2017). NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. J. Exp. Med. 214, 1351–1370.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    DePaula-Silva, A.B., Gorbea, C., Doty, D.J., Libbey, J.E., Sanchez, J.M.S., Hanak, T.J., Cazalla, D., Fujinami, R.S. (2019). Differential transcriptional profiles identify microglial- and macrophage-specific gene markers expressed during virus-induced neuroinflammation. J. Neuroinflammation 16, 152-019-1545-x.
  71. 71.↵
    Zhao, D., Mokhtari, R., Pedrosa, E., Birnbaum, R., Zheng, D., Lachman, H.M. (2017). Transcriptome analysis of microglia in a mouse model of Rett syndrome: differential expression of genes associated with microglia/macrophage activation and cellular stress. Mol. Autism 8, 17-017-0134-z. eCollection 2017.
  72. 72.↵
    Jeong J, Li Y, Roche KW. CaMKII Phosphorylation Regulates Synaptic Enrichment of Shank3. eNeuro. 2021 Feb 9:ENEURO.0481-20.2021. doi: 10.1523/ENEURO.0481-20.2021.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    Lee, K., Vyas, Y., Garner, C.C., Montgomery, J.M. (2019). Autism-associated Shank3 mutations alter mGluR expression and mGluR-dependent but not NMDA receptor-dependent long-term depression. Synapse 73, e22097.
    OpenUrl
  74. 74.
    Duffney, L.J., Wei, J., Cheng, J., Liu, W., Smith, K.R., Kittler, J.T., Yan, Z. (2013). Shank3 deficiency induces NMDA receptor hypofunction via an actin-dependent mechanism. J. Neurosci. 33, 15767–15778.
    OpenUrlAbstract/FREE Full Text
  75. 75.↵
    Raynaud, F., Janossy, A., Dahl, J., Bertaso, F., Perroy, J., Varrault, A., Vidal, M., Worley, P.F., Boeckers, T.M., Bockaert, J. et al. (2013). Shank3-Rich2 interaction regulates AMPA receptor recycling and synaptic long-term potentiation. J. Neurosci. 33, 9699–9715.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    Alexandrov, P.N., Zhao, Y., Jaber, V., Cong, L., Lukiw, W.J. (2017). Deficits in the Proline-Rich Synapse-Associated Shank3 Protein in Multiple Neuropsychiatric Disorders. Front. Neurol. 8, 670.
    OpenUrl
  77. 77.↵
    Redin, C., Gerard, B., Lauer, J., Herenger, Y., Muller, J., Quartier, A., Masurel-Paulet, A., Willems, M., Lesca, G., El-Chehadeh, S. et al. (2014). Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing. J. Med. Genet.
  78. 78.
    Leblond, C.S., Nava, C., Polge, A., Gauthier, J., Huguet, G., Lumbroso, S., Giuliano, F., Stordeur, C., Depienne, C., Mouzat, K. et al. (2014). Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: a gradient of severity in cognitive impairments. PLoS Genet. 10, e1004580.
    OpenUrlCrossRefPubMed
  79. 79.↵
    Guilmatre, A., Huguet, G., Delorme, R., Bourgeron, T. (2014). The emerging role of SHANK genes in neuropsychiatric disorders. Dev. Neurobiol. 74, 113–122.
    OpenUrlCrossRefPubMed
  80. 80.↵
    Bey, A.L., Gorman, M.P., Gallentine, W., Kohlenberg, T.M., Frankovich, J., Jiang, Y.H., Van Haren, K. (2020). Subacute Neuropsychiatric Syndrome in Girls With SHANK3 Mutations Responds to Immunomodulation. Pediatrics 145, e20191490. doi: 10.1542/peds.2019-1490.
    OpenUrlAbstract/FREE Full Text
  81. 81.↵
    Kohlenberg, T.M., Trelles, M.P., McLarney, B., Betancur, C., Thurm, A., Kolevzon, A. (2020).Psychiatric illness and regression in individuals with Phelan-McDermid syndrome. J Neurodev Disord Feb 12;12(1):7.
    OpenUrl
  82. 82.↵
    Berryer, M.H., Hamdan, F.F., Klitten, L.L., Moller, R.S., Carmant, L., Schwartzentruber, J., Patry, L., Dobrzeniecka, S., Rochefort, D., Neugnot-Cerioli, M. et al. (2013). Mutations in SYNGAP1 cause intellectual disability, autism, and a specific form of epilepsy by inducing haploinsufficiency. Hum. Mutat. 34, 385–394.
    OpenUrlCrossRefPubMed
  83. 83.
    Santos-Gómez, A., Miguez-Cabello, F., García-Recio, A., Locubiche, S., García-Díaz, R., Soto, V., Guerrero-López, R., Juliá-Palacios, N., Ciruela, F., García-Cazorla, À. et al. (2020). Disease-associated GRIN protein truncating variants trigger NMDA receptor loss-of-function. Hum. Mol. Genet.
  84. 84.↵
    Myers, S.J., Yuan, H., Kang, J.Q., Tan, F.C.K., Traynelis, S.F., Low, C.M. (2019). Distinct roles of GRIN2A and GRIN2B variants in neurological conditions. F1000Res 8, doi:10.12688/f1000research.18949.1. eCollection 2019.
    OpenUrlCrossRef
  85. 85.↵
    Strehlow, V., Heyne, H.O., Vlaskamp, D.R.M., Marwick, K.F.M., Rudolf, G., de Bellescize, J., Biskup, S., Brilstra, E.H., Brouwer, O.F., Callenbach, P.M.C. et al. (2019). GRIN2A-related disorders: genotype and functional consequence predict phenotype. Brain 142, 80–92.
    OpenUrlCrossRefPubMed
  86. 86.↵
    Liao, X., Li, Y. (2020). Genetic associations between voltage-gated calcium channels and autism spectrum disorder: a systematic review. Mol. Brain 13, 96-020-00634-0.
  87. 87.↵
    Araki, Y., Hong, I., Gamache, T.R., Ju, S., Collado-Torres, L., Shin, J.H., Huganir, R.L. (2020). SynGAP isoforms differentially regulate synaptic plasticity and dendritic development. Elife 9, doi:10.7554/eLife.56273.
    OpenUrlCrossRef
  88. 88.↵
    Li, J., Zhang, J., Tang, W., Mizu, R.K., Kusumoto, H., XiangWei, W., Xu, Y., Chen, W., Amin, J.B., Hu, C. et al. (2019). De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases. Hum. Mutat. 40, 2393–2413.
    OpenUrl
  89. 89.↵
    Ryan, T.J., Kopanitsa, M.V., Indersmitten, T., Nithianantharajah, J., Afinowi, N.O., Pettit, C., Stanford, L.E., Sprengel, R., Saksida, L.M., Bussey, T.J. et al. (2013). Evolution of GluN2A/B cytoplasmic domains diversified vertebrate synaptic plasticity and behavior. Nat. Neurosci. 16, 25–32.
    OpenUrlCrossRefPubMed
  90. 90.↵
    Seo, B.A., Lee, J.H., Kim, H.M., Kang, M.G. (2018). Neuronal calcium channel α interacts with AMPA receptor, increasing its cell surface localisation. Biochem. Biophys. Res. Commun. 498, 402–408.
    OpenUrl
  91. 91.↵
    Snowden, J.A., Badoglio, M., Alexander, T. (2019). The rise of autologous HCT for autoimmune diseases: what is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party. Expert Rev Clin Immunol. 2019 Oct;15(10):981–985.
    OpenUrl
  92. 92.↵
    Kristinsson, S.Y., Landgren, O., Sjöberg, J., Turesson, I., Björkholm, M., Goldin, L.R. (2009). Autoimmunity and risk for Hodgkin’s lymphoma by subtype. Haematologica 94, 1468–1469.
    OpenUrlFREE Full Text
  93. 93.
    Urayama, K.Y., Jarrett, R.F., Hjalgrim, H., Diepstra, A., Kamatani, Y., Chabrier, A., Gaborieau, V., Boland, A., Nieters, A., Becker, N. et al. (2012). Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J. Natl. Cancer Inst. 104, 240–253.
    OpenUrlCrossRefPubMedWeb of Science
  94. 94.↵
    Nakayama, S., Yokote, T., Hiraoka, N., Nishiwaki, U., Hanafusa, T., Nishimura, Y., Tsuji, M. (2016). Role of mast cells in fibrosis of classical Hodgkin lymphoma. Int. J. Immunopathol. Pharmacol. 29, 603–611.
    OpenUrlCrossRefPubMed
  95. 95.↵
    Nanda, H., Ponnusamy, N., Odumpatta, R., Jeyakanthan, J., Mohanapriya, A. (2020). Exploring genetic targets of psoriasis using genome wide association studies (GWAS) for drug repurposing. 3 Biotech 10, 43-019-2038-4. Epub 2020 Jan 10.
  96. 96.↵
    Li, B., Huang, L., Lv, P., Li, X., Liu, G., Chen, Y., Wang, Z., Qian, X., Shen, Y., Li, Y. et al. (2020). The role of Th17 cells in psoriasis. Immunol. Res. 68, 296–309.
    OpenUrl
  97. 97.↵
    Wang, T., Hoekzema, K., Vecchio, D., Wu, H., Sulovari, A., Coe, B.P., Gillentine, M.A., Wilfert, A.B., Perez-Jurado, L.A., Kvarnung, M. et al. (2020). Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders. Nat. Commun. 11, 4932-020-18723-y.
  98. 98.↵
    Li, X., Guo, S., Liu, K., Zhang, C., Chang, H., Yang, W., Rong, S., Hu, Q., Cui, J., Wang, F. et al. (2020). GABRG2 Deletion Linked to Genetic Epilepsy with Febrile Seizures Plus Affects the Expression of GABA(A) Receptor Subunits and Other Genes at Different Temperatures. Neuroscience 438, 116–136.
    OpenUrl
  99. 99.↵
    Jiang, Y.L., Song, C., Wang, Y., Zhao, J., Yang, F., Gao, Q., Leng, X., Man, Y., Jiang, W. (2020). Clinical Utility of Exome Sequencing and Reinterpreting Genetic Test Results in Children and Adults With Epilepsy. Front. Genet. 11, 591434.
    OpenUrl
  100. 100.↵
    Li, J., Liu, Y., Li, Q., Huang, X., Zhou, D., Xu, H., Zhao, F., Mi, X., Wang, R., Jia, F. et al. (2020). Mutation in ε-Sarcoglycan Induces a Myoclonus-Dystonia Syndrome-Like Movement Disorder in Mice. Neurosci. Bull.
  101. 101.↵
    Yankova, G., Bogomyakova, O., Tulupov, A. (2021). The glymphatic system and meningeal lymphatics of the brain: new understanding of brain clearance. Rev. Neurosci.
  102. 102.
    Manouchehrian, O., Ramos, M., Bachiller, S., Lundgaard, I., Deierborg, T. (2021). Acute systemic LPS-exposure impairs perivascular CSF distribution in mice. J. Neuroinflammation 18, 34-021-02082-6.
  103. 103.↵
    Nedergaard, M., Goldman, S.A. (2020). Glymphatic failure as a final common pathway to dementia. Science 370, 50–56.
    OpenUrlAbstract/FREE Full Text
  104. 104.↵
    LeDoux, M.S. (2020). Population Prevalence of Deleterious SGCE Variants. Tremor Other Hyperkinet Mov. (N. Y) 10, 50.
  105. 105.
    Delgado-Alvarado, M., Matilla-Dueñas, A., Altadill-Bermejo, A., Setién, S., Misiego-Peral, M., Sánchez-de la Torre, J.R., Corral-Juan, M., Riancho, J. (2020). A novel SGCE variant is associated with myoclonus-dystonia with phenotypic variability. Neurol. Sci. 41, 3779–3781.
    OpenUrl
  106. 106.↵
    Peall, K.J., Smith, D.J., Kurian, M.A., Wardle, M., Waite, A.J., Hedderly, T., Lin, J.P., Smith, M., Whone, A., Pall, H. et al. (2013). SGCE mutations cause psychiatric disorders: clinical and genetic characterization. Brain 136, 294–303.
    OpenUrlCrossRefPubMedWeb of Science
  107. 107.↵
    Fernández-Marmiesse, A., Kusumoto, H., Rekarte, S., Roca, I., Zhang, J., Myers, S.J., Traynelis, S.F., Couce, M.L., Gutierrez-Solana, L., Yuan, H. (2018). A novel missense mutation in GRIN2A causes a nonepileptic neurodevelopmental disorder. Mov. Disord. 33, 992–999.
    OpenUrlCrossRef
  108. 108.
    Coco_, R., Raicu, F., Băjenaru, O.L., Olaru, I., Dumitrescu, L., Popescu, B.O. (2020). CACNA1B gene variants in adult-onset isolated focal dystonia. Neurol. Sci.
  109. 109.
    Klitten, L.L., Møller, R.S., Nikanorova, M., Silahtaroglu, A., Hjalgrim, H., Tommerup, N. (2011). A balanced translocation disrupts SYNGAP1 in a patient with intellectual disability, speech impairment, and epilepsy with myoclonic absences (EMA). Epilepsia 52, e190–3.
    OpenUrlCrossRefPubMed
  110. 110.↵
    von Stülpnagel, C., Hartlieb, T., Borggräfe, I., Coppola, A., Gennaro, E., Eschermann, K., Kiwull, L., Kluger, F., Krois, I., Møller, R.S. et al. (2019). Chewing induced reflex seizures (“eating epilepsy”) and eye closure sensitivity as a common feature in pediatric patients with SYNGAP1 mutations: Review of literature and report of 8 cases. Seizure 65, 131–137.
    OpenUrl
  111. 111.↵
    Manthiram, K., Zhou, Q., Aksentijevich, I., Kastner, D.L. (2017). The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat. Immunol. 18, 832–842.
    OpenUrlCrossRefPubMed
  112. 112.↵
    Taniguchi, K., Karin, M. (2018). NF-κB, inflammation, immunity and cancer: coming of age. Nat. Rev. Immunol. 18, 309–324.
    OpenUrlCrossRefPubMed
  113. 113.↵
    Liu, T., Zhang, L., Joo, D., Sun, S.C. (2017). NF-κB signaling in inflammation. Signal. Transduct Target Ther. 2, 17023.
    OpenUrl
  114. 114.↵
    Comeau, K., Paradism P., Schiffrin, E.L. (2000). Human and murine memory gammadelta T cells: Evidence for acquired immune memory in bacterial and viral infections and autoimmunity. Cell Immunol. Nov;357:104217. doi: 10.1016/j.cellimm.2020.104217. Epub 2020 Sep 16.
    OpenUrlCrossRef
  115. 115.↵
    Li, Y., Zhang, Y., Zeng, X. (2021). γδ T Cells Participating in Nervous Systems: A Story of Jekyll and Hyde. Front Immunol. Mar 31; 12:656097. Published online 2021 Mar 31. doi: 10.3389/fimmu.2021.656097
    OpenUrlCrossRef
  116. 116.↵
    Alves de Lima, K., Rustenhoven, J., Da Mesquita, S., Wall, M., Salvador, A.F., Smirnov, I., Cebinelli, G.M., Mamuladze, T., Baker, W., Papadopoulos, Z, et al. (2020). Meningeal γδ T cells regulate anxiety-like behavior via IL-17a signaling in neurons. Nat Immunol. Nov;21(11):1421–1429.
    OpenUrl
  117. 117.↵
    Korzh, V. (2018). Development of brain ventricular system. Cell Mol,. Life Sci. 75, 375–383.
    OpenUrl
  118. 118.↵
    Javed, K., Reddy, V., Lui, F. (2021). Neuroanatomy, Choroid Plexus. In StatPearls, Anonymous (Treasure Island (FL): StatPearls Publishing LLC).
  119. 119.↵
    Hubert, V., Dumot, C., Ong, E., Amaz, C., Canet-Soulas, E., Chauveau, F., Wiart, M. (2019). MRI coupled with clinically-applicable iron oxide nanoparticles reveals choroid plexus involvement in a murine model of neuroinflammation. Sci. Rep. 9, 10046-019-46566-1.
  120. 120.
    Prinz, M., Masuda, T., Wheeler, M.A., Quintana, F.J. (2021). Microglia and Central Nervous System-Associated Macrophages-From Origin to Disease Modulation. Annu. Rev. Immunol.
  121. 121.↵
    Huang, X., Hussain, B., Chang, J. (2021). Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms. CNS Neurosci. Ther. 27, 36–47.
    OpenUrl
  122. 122.↵
    Earl, R.K., Turner, T.N., Mefford, H.C., Hudac, C.M., Gerdts, J., Eichler, E.E., Bernier, R.A. (2017). Clinical phenotype of ASD-associated DYRK1A haploinsufficiency. Mol. Autism 8, 54-017-0173-5. eCollection 2017.
  123. 123.
    O’Roak, B.J., Vives, L., Fu, W., Egertson, J.D., Stanaway, I.B., Phelps, I.G., Carvill, G., Kumar, A., Lee, C., Ankenman, K. et al. (2012). Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 338, 1619–1622.
    OpenUrlAbstract/FREE Full Text
  124. 124.↵
    Dang, T., Duan, W.Y., Yu, B., Tong, D.L., Cheng, C., Zhang, Y.F., Wu, W., Ye, K., Zhang, W.X., Wu, M. et al. (2018). Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development. Mol. Psychiatry 23, 747–758.
    OpenUrlCrossRefPubMed
  125. 125.↵
    Cerboni, S., Gehrmann, U., Preite, S., Mitra, S. (2020). Cytokine-regulated Th17 plasticity in human health and diseases. Immunology.
  126. 126.
    Cerboni, S., Gehrmann, U., Preite, S., Mitra, S. (2020). Cytokine-regulated Th17 plasticity in human health and diseases. Immunology.
  127. 127.
    Zhang, R., Miao, J., Zhu, P. (2020). Regulatory T cell heterogeneity and therapy in autoimmune diseases. Autoimmun. Rev., 102715.
  128. 128.
    Rosado-Sánchez, I., Levings, M.K. (2020). Building a CAR-Treg: Going from the basic to the luxury model. Cell. Immunol. 358, 104220.
    OpenUrl
  129. 129.↵
    Khor, B., Gagnon, J.D., Goel, G., Roche, M.I., Conway, K.L., Tran, K., Aldrich, L.N., Sundberg, T.B., Paterson, A.M., Mordecai, S. et al. (2015). The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells. Elife 4, doi:10.7554/eLife.05920.
    OpenUrlCrossRef
  130. 130.↵
    Platt, M.P., Bolding, K.A., Wayne, C.R., Chaudhry, S., Cutforth, T., Franks, K.M., Agalliu, D. (2020). Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitis. Proc. Natl. Acad. Sci. U. S. A. 117, 6708–6716.
    OpenUrlAbstract/FREE Full Text
  131. 131.
    Cutforth, T., DeMille, M.M., Agalliu, I., Agalliu, D. (2016). CNS autoimmune disease after Streptococcus pyogenes infections: animal models, cellular mechanisms and genetic factors. Future Neurol. 11, 63–76.
    OpenUrl
  132. 132.↵
    Dileepan, T., Smith, E.D., Knowland, D., Hsu, M., Platt, M., Bittner-Eddy, P., Cohen, B., Southern, P., Latimer, E., Harley, E. et al. (2016). Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells. J. Clin. Invest. 126, 303–317.
    OpenUrlCrossRef
  133. 133.↵
    Choi, D.W., Na, W., Kabir, M.H., Yi, E., Kwon, S., Yeom, J., Ahn, J.W., Choi, H.H., Lee, Y., Seo, K.W. et al. (2013). WIP1, a homeostatic regulator of the DNA damage response, is targeted by HIPK2 for phosphorylation and degradation. Mol. Cell 51, 374–385.
    OpenUrlCrossRefPubMed
  134. 134.↵
    Xu, L., Fang, H., Xu, D., Wang, G. (2020). HIPK2 sustains inflammatory cytokine production by promoting endoplasmic reticulum stress in macrophages. Exp. Ther. Med. 20, 171.
    OpenUrl
  135. 135.↵
    Li, R., Shang, J., Zhou, W., Jiang, L., Xie, D., Tu, G. (2018). Overexpression of HIPK2 attenuates spinal cord injury in rats by modulating apoptosis, oxidative stress, and inflammation. Biomed. Pharmacother. 103, 127–134.
    OpenUrl
  136. 136.↵
    Lewin, A.B., Storch, E.A., Murphy, T.K. (2011). Pediatric autoimmune neuropsychiatric disorders associated with Streptococcus in identical siblings. J. Child Adolesc. Psychopharmacol. 21, 177–182.
    OpenUrlPubMed
  137. 137.↵
    Gan, L., O’Hanlon, T.P., Gordon, A.S., Rider, L.G., Miller, F.W., Burbelo, P.D. (2014). Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis. BMC Musculoskelet. Disord. 15, 67-2474-15-67.
  138. 138.↵
    Moretti, R., Pansiot, J., Bettati, D., Strazielle, N., Ghersi-Egea, J.F., Damante, G., Fleiss, B., Titomanlio, L., Gressens, P. (2015). Blood-brain barrier dysfunction in disorders of the developing brain. Front. Neurosci. 9, 40.
    OpenUrlCrossRefPubMed
  139. 139.↵
    Huett, A., Leong, J.M., Podolsky, D.K., Xavier, R.J. (2009). The cytoskeletal scaffold Shank3 is recruited to pathogen-induced actin rearrangements. Exp. Cell Res. 315, 2001–2011.
    OpenUrlPubMed
  140. 140.↵
    Zhen, H., Zhao, L., Ling, Z., Kuo, L., Xue, X., Feng, J. (2018). Wip1 regulates blood-brain barrier function and neuro-inflammation induced by lipopolysaccharide via the sonic hedgehog signaling signaling pathway. Mol. Immunol. 93, 31–37.
    OpenUrlPubMed
  141. 141.↵
    Goasdoué, K., Miller, S.M., Colditz, P.B., Björkman, S.T. (2017). Review: The blood-brain barrier; protecting the developing fetal brain. Placenta 54, 111–116.
    OpenUrlCrossRef
  142. 142.↵
    Lombardo, M.V., Moon, H.M., Su, J., Palmer, T.D., Courchesne, E., Pramparo, T. (2018). Maternal immune activation dysregulation of the fetal brain transcriptome and relevance to the pathophysiology of autism spectrum disorder. Mol. Psychiatry 23, 1001–1013.
    OpenUrlCrossRefPubMed
  143. 143.↵
    Spann, M.N., Monk, C., Scheinost, D., Peterson, B.S. (2018). Maternal Immune Activation During the Third Trimester Is Associated with Neonatal Functional Connectivity of the Salience Network and Fetal to Toddler Behavior. J. Neurosci. 38, 2877–2886.
    OpenUrlAbstract/FREE Full Text
  144. 144.↵
    Ducharme, G., Lowe, G.C., Goutagny, R., Williams, S. (2012). Early alterations in hippocampal circuitry and theta rhythm generation in a mouse model of prenatal infection: implications for schizophrenia. PLoS One 7, e29754.
    OpenUrlCrossRefPubMed
  145. 145.
    Arnold, S.E., Franz, B.R., Gur, R.C., Gur, R.E., Shapiro, R.M., Moberg, P.J., Trojanowski, J.Q. (1995). Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am. J. Psychiatry 152, 738–748.
    OpenUrlCrossRefPubMedWeb of Science
  146. 146.
    Benes, F.M. (2011). Regulation of cell cycle and DNA repair in post-mitotic GABA neurons in psychotic disorders. Neuropharmacology 60, 1232–1242.
    OpenUrlCrossRefPubMedWeb of Science
  147. 147.
    Benes, F.M., Lim, B., Matzilevich, D., Subburaju, S., Walsh, J.P. (2008). Circuitry-based gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus bipolars. Proc. Natl. Acad. Sci. U. S. A. 105, 20935–20940.
    OpenUrlAbstract/FREE Full Text
  148. 148.
    Benes, F.M., Lim, B., Matzilevich, D., Walsh, J.P., Subburaju, S., Minns, M. (2007). Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc. Natl. Acad. Sci. U. S. A. 104, 10164–10169.
    OpenUrlAbstract/FREE Full Text
  149. 149.
    Smith, S.E., Li, J., Garbett, K., Mirnics, K., Patterson, P.H. (2007). Maternal immune activation alters fetal brain development through interleukin-6. J. Neurosci. 27, 10695–10702.
    OpenUrlAbstract/FREE Full Text
  150. 150.
    Bauman, M.D., Iosif, A.M., Smith, S.E., Bregere, C., Amaral, D.G., Patterson, P.H. (2014). Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring. Biol. Psychiatry 75, 332–341.
    OpenUrlCrossRefPubMed
  151. 151.
    Meyer, U., Feldon, J., Fatemi, S.H. (2009). In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders. Neurosci. Biobehav. Rev. 33, 1061–1079.
    OpenUrlCrossRefPubMedWeb of Science
  152. 152.↵
    Oskvig, D.B., Elkahloun, A.G., Johnson, K.R., Phillips, T.M., Herkenham, M. (2012). Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response. Brain Behav. Immun. 26, 623–634.
    OpenUrlCrossRefPubMed
  153. 153.↵
    Lünemann, J.D., Nimmerjahn, F., Dalakas, M.C. (2015). Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. Nat. Rev. Neurol. 11, 80–89.
    OpenUrlCrossRefPubMed
  154. 154.
    Norris, P.A.A., Kaur, G., Lazarus, A.H. (2020). New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases. Curr. Opin. Hematol. 27, 392–398.
    OpenUrl
  155. 155.
    Bayry, J., Thirion, M., Misra, N., Thorenoor, N., Delignat, S., Lacroix-Desmazes, S., Bellon, B., Kaveri, S., Kazatchkine, M.D. (2003). Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol. Sci. 24 Suppl 4, S217–21.
    OpenUrlCrossRefPubMed
  156. 156.↵
    Poetsch, V., Neuhaus, W., Noe, C.R. (2010). Serum-derived immunoglobulins neutralize adverse effects of amyloid-beta peptide on the integrity of a blood-brain barrier in vitro model. J. Alzheimers Dis. 21, 303–314.
    OpenUrlPubMed
  157. 157.↵
    Jones, H.F., Ho, A.C.C., Sharma, S., Mohammad, S.S., Kothur, K., Patel, S., Brilot, F., Guastella, A.J., Dale, R.C., Immune-Neurodevelopment (Imm-Nd) Study Group. (2019). Maternal thyroid autoimmunity associated with acute-onset neuropsychiatric disorders and global regression in offspring. Dev. Med. Child Neurol. 61, 984–988.
    OpenUrl
  158. 158.
    Lin, J.R., Cai, Y., Zhang, Q., Zhang, W., Nogales-Cadenas, R., Zhang, Z.D. (2016). Integrated Post-GWAS Analysis Sheds New Light on the Disease Mechanisms of Schizophrenia. Genetics 204, 1587–1600.
    OpenUrlAbstract/FREE Full Text
  159. 159.
    García-Cuesta, E.M., Santiago, C.A., Vallejo-Díaz, J., Juarranz, Y., Rodríguez-Frade, J.M., Mellado, M. (2019). The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases. Front. Endocrinol. (Lausanne) 10, 585.
    OpenUrl
  160. 160.
    Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V. et al. (2016). Schizophrenia risk from complex variation of complement component 4. Nature 530, 177–183.
    OpenUrlCrossRefPubMed
  161. 161.
    Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421–427.
    OpenUrlCrossRefPubMedWeb of Science
  162. 162.
    Hafizi, S., Tabatabaei, D., Lai, M.C. (2019). Review of Clinical Studies Targeting Inflammatory Pathways for Individuals With Autism. Front. Psychiatry. 10, 849.
    OpenUrl
  163. 163.
    Atladóttir, H.O., Pedersen, M.G., Thorsen, P., Mortensen, P.B., Deleuran, B., Eaton, W.W., Parner, E.T. (2009). Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 124, 687–694.
    OpenUrlAbstract/FREE Full Text
  164. 164.↵
    Lyall, K., Ames, J.L., Pearl, M., Traglia, M., Weiss, L.A., Windham, G.C., Kharrazi, M., Yoshida, C.K., Yolken, R., Volk, H.E. et al. (2021). A profile and review of findings from the Early Markers for Autism study: unique contributions from a population-based case-control study in California. Mol. Autism 12, 24-021-00429-7.
  165. 165.↵
    Dantzer, R. (2018). Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa. Physiol. Rev. 98, 477–504.
    OpenUrlCrossRefPubMed
  166. 166.↵
    Quagliariello, A., Del Chierico, F., Russo, A., Reddel, S., Conte, G., Lopetuso, L.R., Ianiro, G., Dallapiccola, B., Cardona, F., Gasbarrini, A. et al. (2018). Gut Microbiota Profiling and Gut-Brain Crosstalk in Children Affected by Pediatric Acute-Onset Neuropsychiatric Syndrome and Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. Front. Microbiol. 9, 675.
    OpenUrl
  167. 167.↵
    Pellegrini, C., Antonioli, L., Calderone, V., Colucci, R., Fornai, M., Blandizzi, C. (2020). Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? Prog. Neurobiol. 191, 101806.
    OpenUrl
  168. 168.↵
    Loffredo, L., Spalice, A., Salvatori, F., De Castro, G., Guido, C.A., Zicari, A.M., Ciacci, P., Battaglia, S., Brindisi, G., Ettorre, E. et al. (2020). Oxidative stress and gut-derived lipopolysaccharides in children affected by paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. BMC Pediatr. 20, 127-020-02026-8.
  169. 169.↵
    Sauer, A.K., Bockmann, J., Steinestel, K., Boeckers, T.M., Grabrucker, A.M. (2019). Altered Intestinal Morphology and Microbiota Composition in the Autism Spectrum Disorders Associated SHANK3 Mouse Model. Int. J. Mol. Sci. 20, 2134. doi: 10.3390/ijms20092134.
    OpenUrlCrossRef
  170. 170.↵
    Wei, S.C., Yang-Yen, H.F., Tsao, P.N., Weng, M.T., Tung, C.C., Yu, L.C.H., Lai, L.C., Hsiao, J.H., Chuang, E.Y., Shun, C.T. et al. (2017). SHANK3 Regulates Intestinal Barrier Function Through Modulating ZO-1 Expression Through the PKCε-dependent Pathway. Inflamm. Bowel Dis. 23, 1730–1740.
    OpenUrl
  171. 171.↵
    Rodrigues, F., Hentgen, V., Bachmeyer, C., Kone-Paut, I., Belot, A., Grateau, G., Sarrabay, G., Georgin-Lavialle, S. (2018). [NLRC4 associated autoinflammatory diseases: A systematic review of the current literature]. Rev Med Interne. 2018 Apr;39(4):279–286.2
    OpenUrl
  172. 172.↵
    Opipari, A., Franchi, L,. Role of inflammasomes in intestinal inflammation and Crohn’s disease. (2015). Inflamm Bowel Dis. Jan;21(1):173–81.
    OpenUrl
  173. 173.↵
    Tse, J.K.Y. (2017). Gut Microbiota, Nitric Oxide, and Microglia as Prerequisites for Neurodegenerative Disorders. ACS Chem. Neurosci. 8, 1438–1447.
    OpenUrl
  174. 174.
    Esposito, G., Sarnelli, G., Capoccia, E., Cirillo, C., Pesce, M., Lu, J., Calì, G., Cuomo, R., Steardo, L. (2016). Autologous transplantation of intestine-isolated glia cells improves neuropathology and restores cognitive deficits in β amyloid-induced neurodegeneration. Sci. Rep. 6, 22605.
    OpenUrlCrossRefPubMed
  175. 175.
    Niesler, B., Kuerten, S., Demir, I.E., Schäfer, K.H. (2021). Disorders of the enteric nervous system - a holistic view. Nat. Rev. Gastroenterol. Hepatol.
  176. 176.
    Jakob, M.O., Murugan, S., Klose, C.S.N. (2020). Neuro-Immune Circuits Regulate Immune Responses in Tissues and Organ Homeostasis. Front. Immunol. 11, 308.
    OpenUrl
  177. 177.↵
    Spear, E.T., Mawe, G.M. (2019). Enteric neuroplasticity and dysmotility in inflammatory disease: key players and possible therapeutic targets. Am. J. Physiol. Gastrointest. Liver Physiol. 317, G853–G861.
    OpenUrl
Back to top
Posted June 04, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Identification of ultra-rare genetic variants in Pediatric Acute Onset Neuropsychiatric Syndrome (PANS) by exome and whole genome sequencing
Rosario Trifiletti, Herbert M. Lachman, Olivia Manusama, Deyou Zheng, Alberto Spalice, Pietro Chiurazzi, Allan Schornagel, Andreea M. Serban, Rogier van Wijck, Sigrid Swagemakers, Peter J. van der Spek
medRxiv 2021.05.25.21257256; doi: https://doi.org/10.1101/2021.05.25.21257256
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area